Increased survival and overall tumor rejection was observed when mPD1-Fc-OX40L was administered at either 150 μg or 300 μg per injection (Fig. 5b, Additional file 6: Figure S6A-B). This evidence concerns the gene TNFSF4 and neoplasm.